Search hospitals > Ontario > TORONTO
St. Michael's Hospital
Claim this profileTORONTO, Ontario M5B 1W8
Global Leader in Breast Cancer
Global Leader in Heart Failure
Conducts research for Cardiovascular Disease
Conducts research for Peroneal Nerve Injury
Conducts research for Depression
630 reported clinical trials
54 medical researchers
Summary
St. Michael's Hospital is a medical facility located in TORONTO, Ontario. This center is recognized for care of Breast Cancer, Heart Failure, Cardiovascular Disease, Peroneal Nerve Injury, Depression and other specialties. St. Michael's Hospital is involved with conducting 630 clinical trials across 838 conditions. There are 54 research doctors associated with this hospital, such as Neil Fam, MD, Ron Wald, Amit Atrey, MD, and Sakina Rizvi, PhD.Area of expertise
1Breast Cancer
Global LeaderER positive
HER2 positive
Stage IV
2Heart Failure
Global LeaderStage II
Stage IV
Stage III
Top PIs
Neil Fam, MDSt. Michael's Hospital6 years of reported clinical research
Studies Mitral Regurgitation
Studies Mitral Valve Regurgitation
16 reported clinical trials
18 drugs studied
Ron WaldSt. Michael's Hospital1 year of reported clinical research
Studies Kidney Disease
Studies Kidney Failure
8 reported clinical trials
16 drugs studied
Amit Atrey, MDSt. Michael's Hospital5 years of reported clinical research
Studies Osteoarthritis
Studies Postoperative Pain
5 reported clinical trials
10 drugs studied
Sakina Rizvi, PhDSt. Michael's Hospital1 year of reported clinical research
Studies Suicide
Studies Depression
5 reported clinical trials
5 drugs studied
Clinical Trials running at St. Michael's Hospital
Breast Cancer
Mitral Regurgitation
Stroke
Mitral Valve Regurgitation
Atrial Fibrillation
Coronavirus
Multiple Myeloma
Acute Kidney Injury
Major Depressive Disorder
Von Willebrand Disease
T-DM1 + Tucatinib
for Breast Cancer
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone.
Recruiting1 award Phase 313 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at St. Michael's Hospital?
Where is St. Michael's Hospital located?
Who should I call to ask about financial aid or insurance network?
What insurance does St. Michael's Hospital accept?
What awards or recognition has St. Michael's Hospital received?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.